FANFARE ENTERTAINMENT And Mend Programmatics, Inc. (MPI) Combine Forces To Create Groundbreaking Technology Products For Alzheimer's Disease

15 Dec, 2015, 08:02 ET from MPI Inc.

NOVATO, Calif., Dec. 15, 2015 /PRNewswire/ -- MPI recently closed its software and application creation partnership with Silicon Valley's acclaimed mobile engagement platform company FANFARE ENTERTAINMENT'S Apollo Health division, which will provide unique software and applications for MPI and their endeavors in 21st Century Health.

FANFARE CEO Lance Kelly, who was recently elected to join the MPI Board of Directors, said, "Fanfare could not be more excited about extending its deep software platform engagement expertise and app creation history further into the Healthcare vertical through MPIFANFARE is honored to be partnered with industry luminaries Dr. Dale Bredesen and Thom Mount in this new venture and welcome them into the FANFARE family."

Dr. Bredesen commented, "With his considerable leadership experience and successful track record in developing and delivering engaging consumer software products and solutions, we are delighted to have Lance Kelly on the MPI Board. The inventive use of software in the battle against Alzheimer's disease is a necessary step toward reducing the global burden of dementia. We are dedicated to pioneering novel, 21st-century solutions to chronic illnesses, and our partnership promises to distribute broadly the positive outcomes of our recent and continuing research."

Dr. Bredesen is an acknowledged leader in the field of Alzheimer's research, utilizing programmatics rather than outmoded monotherapeutics. Bredesen published the first paper to describe the reversal of cognitive decline in patients with early Alzheimer's disease or its precursors (Bredesen, Aging 2014), using the Metabolic Enhancement for Neurodegeneration protocol he developed based on 25 years of basic research into the underlying mechanisms of neurodegeneration.

The protocol developed by Bredesen has now been utilized by over 100 participants with early Alzheimer's disease or its precursors MCI or SCI, with a majority showing improvement in symptoms and many able to remain at work or return to work.

MPI Inc. will have a website live for interested parties by mid-late January 2016 see http://www.mpitherapeutics.com for more details.

Media Contact:

Todd Brodginski
todd@ReckoningPR.com
323-654-1900

 

SOURCE MPI Inc.